Clinical trials: Metastatic or Unresectable Solid Tumors
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
This phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have spread to other places in the body…
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04266912
- Testing
- Avelumab, Berzosertib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
This phase II trial studies how well ultrasound-guided verteporfin photodynamic therapy works for the treatment of patients with solid pancreatic tumors that cannot be removed by surgery (unresectable) or pancreatic cancer that…
- Conditions
- Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Neoplasm
- Trial name
- NCT03033225
- Testing
- Endoscopic Ultrasound, Fluorescence Imaging, Photodynamic Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Locally Advanced (Unresectable) or Metastatic Solid Tumors
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07646626
- Testing
- SSGJ-705, SSGJ-612, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Unspecified Adult Solid Tumor, Protocol Specific
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies
This phase I trial is studying the side effects, best way to give, and best dose of gamma-secretase inhibitor RO4929097 in treating patients with metastatic or unresectable solid malignancies.
- Trial name
- NCT01096355
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacogenomic studies
- Where
- 3 sites in Canada
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer
- Trial name
- NCT00004095
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Gastric Adenocarcinoma, Advanced Solid Tumors
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, when administered as a single…
- Conditions
- Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03852251
- Testing
- AK104, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Akeso
Solid Tumors
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess…
- Trial name
- NCT07537881
- Testing
- RC288 For Injection
- Where
- 14 sites in China
- Volunteers
- 326 people
- Sponsor
- RemeGen Co., Ltd.
Solid Tumor, Lymphoma
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Identification of T cell inhibitory signals, including PD-1/PD-L1, has prompted the development of a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance…
- Trial name
- NCT03991559
- Testing
- Manganese Chloride, Anti-PD-1 antibody, Systemic therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Solid Tumor
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
- Trial name
- NCT02536469
- Testing
- HuMax-IL8
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, HRS-1358 ,or HRS-9813 and HRS-8080，or letrozole and trastuzumab, with or without pertuzumab…
- Trial name
- NCT06555068
- Testing
- HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole
- Where
- China
- Volunteers
- 528 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic or unresectable solid tumors.
- Trial name
- NCT00004242
- Testing
- fluorouracil, gemcitabine hydrochloride, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Solid Tumor
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of…
- Trial name
- NCT06873854
- Testing
- LM-108, Toripalimab
- Where
- China
- Volunteers
- 84 people
- Sponsor
- LaNova Medicines Limited
Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of veliparib, cyclophosphamide, and doxorubicin hydrochloride when given together in treating patients solid tumors or non-Hodgkin lymphoma that has spread to other areas…
- Conditions
- Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Neoplasm
- Trial name
- NCT00740805
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
MSI-H/dMMR Solid Tumor
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy, pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with previously-treated locally advanced unresectable…
- Trial name
- NCT04547101
- Testing
- AK104
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Akeso
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Solid Tumor, RAS Mutation
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ASKC189 in in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
- Trial name
- NCT07836036
- Testing
- ASKC189
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.